SG11201705552QA - Anti-pd-l1 antibodies - Google Patents

Anti-pd-l1 antibodies

Info

Publication number
SG11201705552QA
SG11201705552QA SG11201705552QA SG11201705552QA SG11201705552QA SG 11201705552Q A SG11201705552Q A SG 11201705552QA SG 11201705552Q A SG11201705552Q A SG 11201705552QA SG 11201705552Q A SG11201705552Q A SG 11201705552QA SG 11201705552Q A SG11201705552Q A SG 11201705552QA
Authority
SG
Singapore
Prior art keywords
antibodies
Prior art date
Application number
SG11201705552QA
Other languages
English (en)
Inventor
Cheng-I Wang
Hsueh Ling Janice Oh
Siok Ping Yeo
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201705552QA publication Critical patent/SG11201705552QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
SG11201705552QA 2015-01-09 2016-01-04 Anti-pd-l1 antibodies SG11201705552QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1500319.7A GB201500319D0 (en) 2015-01-09 2015-01-09 Anti-PD-L1 antibodies
PCT/SG2016/050001 WO2016111645A1 (en) 2015-01-09 2016-01-04 Anti-pd-l1 antibodies

Publications (1)

Publication Number Publication Date
SG11201705552QA true SG11201705552QA (en) 2017-08-30

Family

ID=52597403

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705552QA SG11201705552QA (en) 2015-01-09 2016-01-04 Anti-pd-l1 antibodies

Country Status (11)

Country Link
US (4) US10517949B2 (https=)
EP (1) EP3242894B1 (https=)
JP (1) JP6866294B2 (https=)
KR (1) KR102713223B1 (https=)
CN (1) CN107428832B (https=)
AU (1) AU2016205518B2 (https=)
CA (1) CA2973332C (https=)
ES (1) ES2835869T3 (https=)
GB (1) GB201500319D0 (https=)
SG (1) SG11201705552QA (https=)
WO (1) WO2016111645A1 (https=)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
WO2018024237A1 (zh) * 2016-08-04 2018-02-08 信达生物制药(苏州)有限公司 抗pd-l1纳米抗体及其应用
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1
CN107773762B (zh) * 2016-08-31 2021-06-15 上海干云生物科技有限公司 基于pd-l1抗体偶联化疗药物的adc及其制备方法和应用
ES2981272T3 (es) 2016-09-23 2024-10-08 Merus Nv Moléculas de unión que modulan una actividad biológica expresada por una célula
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
KR102589422B1 (ko) * 2017-01-09 2023-10-13 바이오뮤넥스 파마슈티컬스 다중특이적 항체를 제조하기 위한 폴리펩티드 링커
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US20200101108A1 (en) * 2017-03-31 2020-04-02 The Board Of Trustees Of The Le-Land Standford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
CA3060573A1 (en) 2017-04-21 2018-10-25 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
CN110799546B (zh) * 2017-09-01 2023-01-24 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
WO2019083971A1 (en) 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
EP3707162A1 (en) 2017-11-10 2020-09-16 Agency for Science, Technology and Research Il2rbeta/common gamma chain antibodies
KR102150419B1 (ko) * 2017-12-15 2020-09-01 경북대학교 산학협력단 Pd-l1에 결합하는 펩타이드 및 이의 용도
WO2019117690A1 (ko) * 2017-12-15 2019-06-20 경북대학교 산학협력단 Pd-l1에 결합하는 펩타이드 및 이의 용도
EP3728316B1 (en) * 2017-12-19 2025-02-26 invoX Pharma Limited Fc binding fragments comprising a pd-l1 antigen-binding site
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
KR102311838B1 (ko) * 2017-12-27 2021-10-14 주식회사 파멥신 항-pd-l1 항체 및 이의 용도
CN109970857B (zh) * 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
AU2019207535B2 (en) * 2018-01-15 2021-12-23 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
SG11202009258RA (en) 2018-03-23 2020-10-29 Univ Texas Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
CN119101158A (zh) 2018-03-23 2024-12-10 得克萨斯州大学系统董事会 人pd-l2抗体及其使用方法
EP4501355A3 (en) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
US12054556B2 (en) 2018-04-09 2024-08-06 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
MX2020010653A (es) * 2018-04-09 2020-10-28 Origincell Therapeutics Co Ltd Anticuerpo anti-muerte programada-ligando 1 y su uso.
CA3097152A1 (en) * 2018-04-16 2019-10-24 Memorial Sloan Kettering Cancer Center T-cell exhaustion, & methods & compositions relating thereto
CA3097369A1 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EP3788079A4 (en) * 2018-05-03 2022-12-21 Shanghai Epimab Biotherapeutics Co., Ltd. ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF
CA3100349A1 (en) * 2018-05-17 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811403D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
PT3820569T (pt) 2018-07-12 2025-01-14 Invox Pharma Ltd Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
US20210246219A1 (en) 2018-08-27 2021-08-12 Pieris Pharmaceuticals Gmbh Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
KR20210091714A (ko) * 2018-10-17 2021-07-22 이뮤놈 인코포레이티드 엑소좀-표적 이중 특이적 항체
WO2020084102A2 (en) 2018-10-25 2020-04-30 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
TW202039557A (zh) 2018-11-09 2020-11-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
TW202031683A (zh) 2018-11-09 2020-09-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
US11046769B2 (en) * 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
KR20210121047A (ko) * 2018-12-27 2021-10-07 기가젠, 인코포레이티드 항-pd-l1 결합 단백질 및 이의 사용 방법
WO2020180398A1 (en) * 2019-01-14 2020-09-10 The Regents Of The University Of California Compositions and methods for modulating cellular internalization
WO2020150282A1 (en) * 2019-01-18 2020-07-23 Askgene Pharma Inc. Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
WO2020209645A1 (ko) * 2019-04-11 2020-10-15 (재) 스크립스코리아항체연구원 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP4017882A4 (en) * 2019-08-23 2023-09-27 Wuxi Biologics Ireland Limited Humanized antibodies against pd-l1
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
CA3169523A1 (en) 2020-02-28 2021-09-02 Jaume Pons Transglutaminase-mediated conjugation
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
US20240067728A1 (en) * 2020-11-06 2024-02-29 Bio-Thera Solutions, Ltd. Bispecific antibody and use thereof
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
CN114478789B (zh) * 2021-12-20 2024-06-14 安徽安科生物工程（集团）股份有限公司 抗pd-l1与ox40双特异性抗体及其用途
CN114470195A (zh) * 2022-01-19 2022-05-13 同济大学 一种抗真菌制剂、抑制细胞pd-l1表达的抑制剂及应用
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
CN120302979A (zh) 2022-12-01 2025-07-11 生物技术公司 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
EP4649096A2 (en) * 2023-01-10 2025-11-19 Sana Biotechnology, Inc. Cd19-specific antibody constructs and compositions thereof
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US20250011420A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Proteins that bind sp17 including fully-human anti-sp17 antibodies
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
US12364777B2 (en) * 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
CN120305419B (zh) * 2025-06-17 2025-11-21 中国医学科学院医药生物技术研究所 一种pd-l1靶向性仿生外泌体和包含其的药物组合物及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US98415A (en) * 1869-12-28 Improved folding chair
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
DK1810026T3 (en) * 2004-10-06 2018-07-16 Mayo Found Medical Education & Res B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CA2611861C (en) 2005-06-08 2017-11-28 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of persistent infections
PT1907424E (pt) * 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP3255060A1 (en) * 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) * 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
PL2504364T3 (pl) * 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2012144794A2 (ko) * 2011-04-19 2012-10-26 주식회사 바이오포커스 랩온어칩에 장착되는 마이크로밸브 소자의 제작방법 및 이로부터 제작되는 마이크로밸브 소자
KR101764096B1 (ko) * 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR20220084444A (ko) * 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP3212670B1 (en) 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
CA3060573A1 (en) * 2017-04-21 2018-10-25 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
EP4054612A4 (en) * 2019-11-07 2023-08-02 Baylor College of Medicine ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY
CN115917316B (zh) * 2020-06-12 2025-10-24 新加坡科技研究局 嗜中性粒细胞祖细胞及相关方法和用途

Also Published As

Publication number Publication date
AU2016205518A1 (en) 2017-07-27
GB201500319D0 (en) 2015-02-25
ES2835869T3 (es) 2021-06-23
HK1246324A1 (zh) 2018-09-07
AU2016205518B2 (en) 2021-02-04
EP3242894A1 (en) 2017-11-15
JP6866294B2 (ja) 2021-04-28
KR102713223B1 (ko) 2024-10-07
KR20170102167A (ko) 2017-09-07
JP2018508475A (ja) 2018-03-29
CN107428832B (zh) 2021-01-26
EP3242894B1 (en) 2020-11-04
US20200093922A1 (en) 2020-03-26
US20180002423A1 (en) 2018-01-04
CA2973332A1 (en) 2016-07-14
US12472252B2 (en) 2025-11-18
US20230201345A1 (en) 2023-06-29
US10517949B2 (en) 2019-12-31
US9789183B1 (en) 2017-10-17
CN107428832A (zh) 2017-12-01
US20170319690A1 (en) 2017-11-09
EP3242894A4 (en) 2018-05-30
CA2973332C (en) 2023-08-22
US11534489B2 (en) 2022-12-27
WO2016111645A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
HUS2500002I1 (hu) Újszerû anti-PD-L1 antitestek
ZA201900353B (en) Anti-pd-l1 antibodies
IL262295A (en) Antibodies against pd-l1
IL255727A (en) Novel anti-pd-l1 antibodies
HUS2500024I1 (hu) ANTI-PD-1 ellenanyagok
ZA201803874B (en) Humanized anti-cd73 antibodies
IL257062A (en) New anti-pd-1 antibodies
SG11201705552QA (en) Anti-pd-l1 antibodies
IL250415A0 (en) Antibodies against pd-l1
LT3512547T (lt) Antikūnai prieš pd-1
ES3064846T3 (en) Tau-binding antibodies
GB201521382D0 (en) Antibodies
IL256579A (en) Human antibodies
GB201508180D0 (en) Antibodies
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3
GB201509907D0 (en) Antibodies
GB201503438D0 (en) Antibodies
GB201511196D0 (en) Monoclonal antibodies
GB201518728D0 (en) Antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201514425D0 (en) Antibodies
GB201508444D0 (en) Antibodies
GB201508437D0 (en) Antibodies
GB201507541D0 (en) Antibodies